163 related articles for article (PubMed ID: 19050412)
1. Variability of the in vivo metabolism of clozapine.
Raedler TJ; Hinkelmann K; Wiedemann K
Clin Neuropharmacol; 2008; 31(6):347-52. PubMed ID: 19050412
[TBL] [Abstract][Full Text] [Related]
2. Clozapine and global cognition in schizophrenia.
Rajji TK; Uchida H; Ismail Z; Ng W; Mamo DC; Remington G; Pollock BG; Mulsant BH
J Clin Psychopharmacol; 2010 Aug; 30(4):431-6. PubMed ID: 20631560
[TBL] [Abstract][Full Text] [Related]
3. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.
Rajji TK; Mulsant BH; Davies S; Kalache SM; Tsoutsoulas C; Pollock BG; Remington G
Am J Psychiatry; 2015 Jun; 172(6):579-85. PubMed ID: 25859763
[TBL] [Abstract][Full Text] [Related]
4. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
[No Abstract] [Full Text] [Related]
5. N-desmethylclozapine: is there evidence for its antipsychotic potential?
Mendoza MC; Lindenmayer JP
Clin Neuropharmacol; 2009; 32(3):154-7. PubMed ID: 19483482
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model.
Dal Santo F; Jarratt-Barnham I; González-Blanco L; García-Portilla MP; Bobes J; Fernández-Egea E
Eur Neuropsychopharmacol; 2020 Apr; 33():158-163. PubMed ID: 32057590
[TBL] [Abstract][Full Text] [Related]
7. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients.
Molins C; Carceller-Sindreu M; Navarro H; Carmona C; Piñeiro M; Martínez E; Álvarez E; Portella MJ
Psychiatry Res; 2017 Dec; 258():153-157. PubMed ID: 29024893
[TBL] [Abstract][Full Text] [Related]
8. Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia.
Costa-Dookhan KA; Rajji TK; Tran VN; Bowden S; Mueller DJ; Remington GJ; Agarwal SM; Hahn MK
Sci Rep; 2021 Jan; 11(1):2004. PubMed ID: 33479273
[TBL] [Abstract][Full Text] [Related]
9. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
10. N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors.
Li Z; Huang M; Ichikawa J; Dai J; Meltzer HY
Neuropsychopharmacology; 2005 Nov; 30(11):1986-95. PubMed ID: 15900318
[TBL] [Abstract][Full Text] [Related]
11. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia.
Guitton C; Abbar M; Kinowski JM; Chabrand P; Bressolle F
J Clin Psychopharmacol; 1998 Dec; 18(6):470-6. PubMed ID: 9864080
[TBL] [Abstract][Full Text] [Related]
12. The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus.
Ertuğrul A; Ozdemir H; Vural A; Dalkara T; Meltzer HY; Saka E
Brain Res Bull; 2011 Feb; 84(2):144-50. PubMed ID: 21134422
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice.
Wiebelhaus JM; Vunck SA; Meltzer HY; Porter JH
Behav Pharmacol; 2012 Jun; 23(3):262-70. PubMed ID: 22547022
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients.
González-Esquivel DF; Castro N; Ramírez-Bermúdez J; Custodio V; Rojas-Tomé S; Castro-Román R; Jung-Cook H
Arzneimittelforschung; 2011; 61(6):335-9. PubMed ID: 21827043
[TBL] [Abstract][Full Text] [Related]
15. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors.
Onali P; Olianas MC
Neuropsychopharmacology; 2007 Apr; 32(4):773-85. PubMed ID: 16841075
[TBL] [Abstract][Full Text] [Related]
16. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome.
Sporn AL; Vermani A; Greenstein DK; Bobb AJ; Spencer EP; Clasen LS; Tossell JW; Stayer CC; Gochman PA; Lenane MC; Rapoport JL; Gogtay N
J Am Acad Child Adolesc Psychiatry; 2007 Oct; 46(10):1349-1356. PubMed ID: 17885577
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats--possible involvement of activation of M(1) muscarinic receptors.
Maehara S; Satow A; Hikichi H; Ohta H
Eur J Pharmacol; 2011 Sep; 667(1-3):242-9. PubMed ID: 21658379
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia.
Guitton C; Kinowski JM; Abbar M; Chabrand P; Bressolle F
J Clin Pharmacol; 1999 Jul; 39(7):721-8. PubMed ID: 10392327
[TBL] [Abstract][Full Text] [Related]
19. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.
Humbert-Claude M; Davenas E; Gbahou F; Vincent L; Arrang JM
Psychopharmacology (Berl); 2012 Mar; 220(1):225-41. PubMed ID: 21912901
[TBL] [Abstract][Full Text] [Related]
20. Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
Sarpal DK; Blazer A; Wilson JD; Calabro FJ; Foran W; Kahn CE; Luna B; Chengappa KNR
Schizophr Res; 2022 May; 243():170-177. PubMed ID: 35381515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
